Angiogenesis Modulators Market Report – Research, Industry Analysis Reports and Market Demands

Global Angiogenesis Modulators Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Angiogenesis Modulators Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Angiogenesis Inhibitors
- 1.3.3 Angiogenesis Stimulators
- 1.3.4 Angiogenin
- 1.3.5 Others
1.4 Market Analysis by Mechanism Direction
- 1.4.1 Overview: Global Angiogenesis Modulators Consumption Value by Mechanism Direction: 2021 Versus 2025 Versus 2032
- 1.4.2 Anti-angiogenic Modulators
- 1.4.3 Pro-angiogenic Modulators
- 1.4.4 Bidirectional or Context-dependent Modulators
- 1.4.5 Others
1.5 Market Analysis by Target Breadth
- 1.5.1 Overview: Global Angiogenesis Modulators Consumption Value by Target Breadth: 2021 Versus 2025 Versus 2032
- 1.5.2 Single-target Modulators
- 1.5.3 Dual-target Modulators
- 1.5.4 Multi-target Modulators
- 1.5.5 Others
1.6 Market Analysis by Application
- 1.6.1 Overview: Global Angiogenesis Modulators Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Breast Cancer
- 1.6.3 Colorectal Cancer
- 1.6.4 Lung Cancer
- 1.6.5 Prostate Cancer
- 1.6.6 Others
1.7 Global Angiogenesis Modulators Market Size & Forecast
- 1.7.1 Global Angiogenesis Modulators Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global Angiogenesis Modulators Sales Quantity (2021-2032)
- 1.7.3 Global Angiogenesis Modulators Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: Angiogenesis Modulators by Manufacturer

3.1 Global Angiogenesis Modulators Sales Quantity by Manufacturer (2021-2026)
3.2 Global Angiogenesis Modulators Revenue by Manufacturer (2021-2026)
3.3 Global Angiogenesis Modulators Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Angiogenesis Modulators by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Angiogenesis Modulators Manufacturer Market Share in 2025
- 3.4.3 Top 6 Angiogenesis Modulators Manufacturer Market Share in 2025
3.5 Angiogenesis Modulators Market: Overall Company Footprint Analysis
- 3.5.1 Angiogenesis Modulators Market: Region Footprint
- 3.5.2 Angiogenesis Modulators Market: Company Product Type Footprint
- 3.5.3 Angiogenesis Modulators Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Angiogenesis Modulators Market Size by Region
- 4.1.1 Global Angiogenesis Modulators Sales Quantity by Region (2021-2032)
- 4.1.2 Global Angiogenesis Modulators Consumption Value by Region (2021-2032)
- 4.1.3 Global Angiogenesis Modulators Average Price by Region (2021-2032)
4.2 North America Angiogenesis Modulators Consumption Value (2021-2032)
4.3 Europe Angiogenesis Modulators Consumption Value (2021-2032)
4.4 Asia-Pacific Angiogenesis Modulators Consumption Value (2021-2032)
4.5 South America Angiogenesis Modulators Consumption Value (2021-2032)
4.6 Middle East & Africa Angiogenesis Modulators Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global Angiogenesis Modulators Sales Quantity by Type (2021-2032)
5.2 Global Angiogenesis Modulators Consumption Value by Type (2021-2032)
5.3 Global Angiogenesis Modulators Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global Angiogenesis Modulators Sales Quantity by Application (2021-2032)
6.2 Global Angiogenesis Modulators Consumption Value by Application (2021-2032)
6.3 Global Angiogenesis Modulators Average Price by Application (2021-2032)

7 North America

7.1 North America Angiogenesis Modulators Sales Quantity by Type (2021-2032)
7.2 North America Angiogenesis Modulators Sales Quantity by Application (2021-2032)
7.3 North America Angiogenesis Modulators Market Size by Country
- 7.3.1 North America Angiogenesis Modulators Sales Quantity by Country (2021-2032)
- 7.3.2 North America Angiogenesis Modulators Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe Angiogenesis Modulators Sales Quantity by Type (2021-2032)
8.2 Europe Angiogenesis Modulators Sales Quantity by Application (2021-2032)
8.3 Europe Angiogenesis Modulators Market Size by Country
- 8.3.1 Europe Angiogenesis Modulators Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Angiogenesis Modulators Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific Angiogenesis Modulators Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Angiogenesis Modulators Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Angiogenesis Modulators Market Size by Region
- 9.3.1 Asia-Pacific Angiogenesis Modulators Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Angiogenesis Modulators Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America Angiogenesis Modulators Sales Quantity by Type (2021-2032)
10.2 South America Angiogenesis Modulators Sales Quantity by Application (2021-2032)
10.3 South America Angiogenesis Modulators Market Size by Country
- 10.3.1 South America Angiogenesis Modulators Sales Quantity by Country (2021-2032)
- 10.3.2 South America Angiogenesis Modulators Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa Angiogenesis Modulators Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Angiogenesis Modulators Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Angiogenesis Modulators Market Size by Country
- 11.3.1 Middle East & Africa Angiogenesis Modulators Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Angiogenesis Modulators Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 Angiogenesis Modulators Market Drivers
12.2 Angiogenesis Modulators Market Restraints
12.3 Angiogenesis Modulators Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Angiogenesis Modulators and Key Manufacturers
13.2 Manufacturing Costs Percentage of Angiogenesis Modulators
13.3 Angiogenesis Modulators Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Angiogenesis Modulators Typical Distributors
14.3 Angiogenesis Modulators Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Angiogenesis Modulators market size was valued at US$ 20373 million in 2025 and is forecast to a readjusted size of US$ 30240 million by 2032 with a CAGR of 5.8% during review period.
Angiogenesis Modulators are pharmaceutical or biologically active agents that regulate the formation, maturation, permeability, and regression of new blood vessels, with commercially marketed products currently dominated by inhibitory therapies. Their physical presentation varies by molecular modality and includes sterile clear solutions in single-use vials or prefilled syringes for intravitreal or intravenous administration, as well as oral tablets or capsules for systemic therapy. Structurally, the category mainly covers: biologics that bind VEGF-A, VEGF-B, PlGF, or dual pathways such as Ang-2/VEGF-A, including monoclonal antibodies and fusion proteins; small-molecule kinase inhibitors that block VEGFR1/2/3 and related signaling pathways; and a much smaller group of pro-angiogenic candidates still concentrated in development or niche clinical use. Their mechanism is to modulate endothelial-cell proliferation, migration, tube formation, vascular leakage, and vessel survival, thereby reshaping local blood supply and disease microenvironment. Current suppliers are primarily large pharmaceutical manufacturers, biosimilar developers, and specialist biopharma companies with capabilities in biologics manufacturing, sterile fill-finish, or targeted small-molecule production. Major application scenarios include oncology, neovascular retinal diseases such as wet age-related macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion. In practical market terms, the commercial value of Angiogenesis Modulators is overwhelmingly concentrated in anti-angiogenic products.
Over recent years, the commercial focus of Angiogenesis Modulators has continued to shift toward segments characterized by high barriers to entry, repeated dosing, and clearer reimbursement pathways. The strongest opportunities are coming from next-generation ophthalmic anti-VEGF therapies, expansion of oncology combination regimens, and growing biosimilar penetration. In ophthalmology, faricimab, high-dose aflibercept, and multiple aflibercept and ranibizumab biosimilars are reinforcing a competitive logic centered on longer dosing intervals, improved adherence, and lower payer burden. In oncology, VEGF/VEGFR inhibitors are increasingly positioned not only as standalone anti-vascular agents but also as backbone components in combinations with immunotherapy, chemotherapy, PARP inhibitors, and locoregional treatment. At the same time, population aging is enlarging the patient pool for wet AMD, DME, and RVO-related disease, while rising cancer prevalence and longer treatment duration continue to support demand. Growth therefore comes not only from new molecules, but also from formulation upgrades, prefilled delivery systems, regional access expansion, hospital switching, and reimbursement optimization.
The challenges and restraints are equally visible. First, competition in mature angiogenesis-related indications is already intense, with originator products facing pressure from both biosimilars and same-class competitors, leading to sustained pricing and tender pressure. Second, the benefit of anti-angiogenic therapy remains highly indication-specific and dependent on line of therapy and combination design, while long-term use is constrained by resistance, variable efficacy, and safety management issues such as hypertension, bleeding, proteinuria, thrombosis, impaired wound healing, and intraocular inflammation. Third, even in large ophthalmology markets, conversion dynamics depend heavily on specialist prescribing behavior, injection burden, real-world tolerability, and reimbursement policy; in oncology, usage is strongly shaped by guideline position, evidence quality in combination regimens, and payer negotiations. Fourth, the pro-angiogenic side still has limited commercial conversion, meaning that although the topic name covers all “modulators,” large-scale recurring revenue remains overwhelmingly concentrated in the inhibitory side.
Downstream demand is moving in three clear directions. The first is a shift from simple efficacy toward durability, lower injection frequency, and better fit with outpatient workflow, which is accelerating the move from conventional monoclonal antibodies toward bispecific antibodies, high-dose fusion proteins, and longer-acting delivery approaches in ophthalmology. The second is a transition from single-pathway targeting to use as a mechanistic module within combination therapy, especially in liver cancer, colorectal cancer, renal cell carcinoma, and lung cancer, where anti-VEGF/VEGFR therapies increasingly function as foundational partners in broader regimens. The third is a move from originator-dominated markets to multi-supplier systems. As biosimilars enter, hospitals and payers become more sensitive to access, budget control, sterile manufacturing quality, cold-chain reliability, and real-world evidence. Future growth will therefore not be driven by volume alone, but by a reallocation of share according to durability, affordability, supply reliability, and evidence strength.
This report is a detailed and comprehensive analysis for global Angiogenesis Modulators market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Angiogenesis Modulators market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Angiogenesis Modulators market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Angiogenesis Modulators market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Angiogenesis Modulators market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Angiogenesis Modulators
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Angiogenesis Modulators market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Regeneron, Bayer, Novartis, Eli Lilly, Pfizer, Eisai, Exelixis, Takeda, HUTCHMED, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Angiogenesis Modulators market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Angiogenesis Inhibitors
Angiogenesis Stimulators
Angiogenin
Others
Market segment by Mechanism Direction
Anti-angiogenic Modulators
Pro-angiogenic Modulators
Bidirectional or Context-dependent Modulators
Others
Market segment by Target Breadth
Single-target Modulators
Dual-target Modulators
Multi-target Modulators
Others
Market segment by Application
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
Others
Major players covered
Roche
Regeneron
Bayer
Novartis
Eli Lilly
Pfizer
Eisai
Exelixis
Takeda
HUTCHMED
Amgen
Sandoz
Biocon Biologics
Celltrion
Samsung Bioepis
Biogen
Dr. Reddy’s Laboratories
Hetero
Intas Pharmaceuticals
AVEO Oncology
Innovent Biologics
Shanghai Henlius
Qilu Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Boan Biotech
Chengdu Kanghong Pharmaceutical Group
Genentech
Samsung Bioepis / Biogen
Sandoz / CIMERLI current business
Dr. Reddy’s / Versavo
Biocon / KRABEVA
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Angiogenesis Modulators product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Angiogenesis Modulators, with price, sales quantity, revenue, and global market share of Angiogenesis Modulators from 2021 to 2026.
Chapter 3, the Angiogenesis Modulators competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Angiogenesis Modulators breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Angiogenesis Modulators market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Angiogenesis Modulators.
Chapter 14 and 15, to describe Angiogenesis Modulators sales channel, distributors, customers, research findings and conclusion.

Buy now